Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 8-K (Current Report)
Date: June 11, 2026
Event: Publication of clinical and translational results from the Phase 1 clinical trial of VCN-01 in Head & Neck Squamous Cell Carcinoma (HNSCC) in the journal Clinical Cancer Research.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial results and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the publication of Phase 1 trial data involving 20 adult patients with refractory or metastatic HNSCC who had progressed on prior therapies. The study compared VCN-01 (an oncolytic virus) combined with durvalumab across three arms:
- Arm I (LD Concomitant): Low dose VCN-01 (3.3E12 particles) administered 4 hours prior to durvalumab (6 patients).
- Arm II (LD Sequential): Low dose VCN-01 administered 14 days prior to durvalumab (8 patients).
- Arm II (HD Sequential): High dose VCN-01 (1.0E13 particles) administered 14 days prior to durvalumab (6 patients).
Key Outcomes:
- Median Progression-Free Survival (PFS): 1.6 months (Arm I LD), 3.7 months (Arm II LD), and 2.1 months (Arm II HD).
- Median Overall Survival (OS): 10.3 months (Arm I LD), 15.5 months (Arm II LD), and 17.3 months (Arm II HD).
- Biomarkers: Significant increase in PH20 enzyme levels (indicating viral replication) and upregulation of CD8 and IDO (indicating T-cell infiltration). Reductions in FoxP3, CD25, and CTLA4 suggested decreased tumor immunosuppression.
Outlook, Risks, and Management Commentary
Management Commentary: The data suggests that VCN-01 administration correlates with increased immune system activity and heightened PD-L1 expression in tumors, contributing to improved outcomes when combined with durvalumab. The upregulation of PD-1 and PD-L1 correlated with patient survival.
Risks and Contingencies: The press release furnished with this filing contains "forward-looking" statements subject to risks and uncertainties under the Private Securities Litigation Reform Act of 1995. The filing explicitly states that the information is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed safety data and adverse event profiles not summarized in the 8-K.
- Confirm the specific statistical significance of the survival differences between the three arms.
- Review the company's cash runway and capital requirements, as this filing does not disclose financial status.
- Assess the timeline for potential Phase 2 trial initiation based on these Phase 1 results.
- Monitor regulatory communications regarding the combination of VCN-01 and durvalumab for HNSCC.